Newbury Pharmaceuticals
1.19 SEK
+0.42 %
Less than 1K followers
NEWBRY
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Newbury Pharmaceuticals
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | 5.5 | 10.3 | 36.8 | 31.6 |
| growth-% | 86.1 % | 258.6 % | -14.3 % | |
| EBITDA | -13.7 | -18.3 | -12.3 | -16.3 |
| EBIT | -3.9 | -19.6 | -14.1 | -22.0 |
| Profit before taxes | -3.9 | -19.4 | -15.4 | -23.6 |
| Net income | -3.9 | -19.4 | -15.4 | -23.9 |
| EPS | -0.00 | -1.00 | -0.79 | -0.88 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| EBITDA-% | -247.5 % | -178.5 % | -33.5 % | -51.6 % |
| EBIT-% | -70.7 % | -190.7 % | -38.2 % | -69.6 % |
| ROE | -5.7 % | -39.3 % | -29.7 % | -55.9 % |
| ROI | -4.5 % | -26.6 % | -17.0 % | -30.9 % |